Last reviewed · How we verify
NCT04333472
Piclidenoson for Treatment of COVID-19
Completed
Phase 2
Last updated 22 April 2022
What this trial tests
Phase 2 trial testing Piclidenoson in COVID-19 in 6 participants. Completed in 21 April 2022.
Timeline
6 January 2021
Primary endpoint
6 March 2022
6 March 2022
21 April 2022
Quick facts
| Lead sponsor | Can-Fite BioPharma |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 6 January 2021 |
| Primary completion | 6 March 2022 |
| Estimated completion | 21 April 2022 |
| Sites | 6 locations across Romania, Israel, Bulgaria |
Drugs / interventions tested
- Piclidenoson — full drug profile →
- Placebo
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Coronavirus Infection — all drugs for Coronavirus Infection →
Sponsor
Can-Fite BioPharma — full company profile →
Who can join
18 and older, any sex, with COVID-19 or Coronavirus Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with documented moderate COVID-19 infection will be randomized 1:1 to receive piclidenoson 2 mg Q12H orally with standard supportive care (SSC - intervention arm) or placebo orally with SSC (control arm) for up to 28 days.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794 -
Adenosine and Inflammation: Here, There and Everywhere.
Pasquini S, Contri C, Borea PA, Vincenzi F, et al · · 2021 · cited 122× · PMID 34299305 · DOI 10.3390/ijms22147685 -
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2020 · cited 105× · PMID 32717568 · DOI 10.1016/j.drup.2020.100719 -
Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements.
Pandey A, Nikam AN, Shreya AB, Mutalik SP, et al · · 2020 · cited 80× · PMID 32497632 · DOI 10.1016/j.lfs.2020.117883 -
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895 -
Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives.
Sarkar C, Mondal M, Torequl Islam M, Martorell M, et al · · 2020 · cited 64× · PMID 33041814 · DOI 10.3389/fphar.2020.572870 -
Novel therapeutic approaches for treatment of COVID-19.
Hossein-Khannazer N, Shokoohian B, Shpichka A, Aghdaei HA, et al · · 2020 · cited 36× · PMID 32494931 · DOI 10.1007/s00109-020-01927-6 -
Primed for global coronavirus pandemic: Emerging research and clinical outcome.
Ahamad S, Branch S, Harrelson S, Hussain MK, et al · · 2021 · cited 25× · PMID 33070079 · DOI 10.1016/j.ejmech.2020.112862
Verify or expand the search:
- PubMed search for NCT04333472
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Piclidenoson
Trials testing the same drug.
- NCT07410455 — An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome · Phase 2 · not yet recruiting
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Can-Fite BioPharma trials
Trials by the same sponsor.
- NCT07410455 — An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome · Phase 2 · not yet recruiting
- NCT06387342 — Namodenoson Treatment of Advanced Pancreatic Cancer · Phase 2 · recruiting
- NCT04697810 — Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) · Phase 2 · recruiting
- NCT03168256 — CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis · Phase 3 · completed
- NCT02927314 — A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04333472 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Can-Fite BioPharma
- Last refreshed: 22 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04333472.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing